Thermo Fisher Scientific R&D remained flat by 0.0% to $349.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.6%, from $374.00M to $349.25M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a -0.2% CAGR.
High spending signals a focus on long-term innovation, though it reduces current-period net income.
Expenses related to the innovation, design, and improvement of products and services. In the technology sector, this rep...
Big Tech firms often reinvest a significant percentage of revenue into R&D to maintain market leadership.
is_research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $343.00M | $351.00M | $392.00M | $364.00M | $365.00M | $351.00M | $391.00M | $346.00M | $345.00M | $319.00M | $327.00M | $331.00M | $339.00M | $346.00M | $374.00M | $349.25M | $349.25M | $349.25M | $349.25M |
| QoQ Change | — | +2.3% | +11.7% | -7.1% | +0.3% | -3.8% | +11.4% | -11.5% | -0.3% | -7.5% | +2.5% | +1.2% | +2.4% | +2.1% | +8.1% | -6.6% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +6.4% | +0.0% | -0.3% | -4.9% | -5.5% | -9.1% | -16.4% | -4.3% | -1.7% | +8.5% | +14.4% | +5.5% | +3.0% | +0.9% | -6.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.